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ABSTRACT
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer. 
Despite response to chemotherapy, relapses are frequent and resistance to available 
treatments is often observed in the metastatic setting. Therefore, identification of 
new therapeutic strategies is required. Here we have investigated the effect of the 
mithramycin analog EC-8042 (demycarosil-3D-β-D-digitoxosyl mithramycin SK) on 
TNBC. The drug caused a dose-dependent inhibition of proliferation of a set of TNBC 
cell lines in vitro, and decreased tumor growth in mice xenografted with TNBC cells. 
Mechanistically, EC-8042 caused an arrest in the G2 phase of the cell cycle, coincident 
with an increase in pCDK1 and Wee1 levels in cells treated with the drug. In addition, 
prolonged treatment with the drug also causes apoptosis, mainly through caspase-
independent routes. Importantly, EC-8042 synergized with drugs commonly used in 
the therapy of TNBC in vitro, and potentiated the antitumoral effect of docetaxel in 
vivo. Together, these data suggest that the mithralog EC-8042 exerts an antitumoral 
action on TNBC cells and reinforces the action of standard of care drugs used in the 
therapy of this disease. These characteristics, together with a better toxicology profile 
of EC-8042 with respect to mithramycin, open the possibility of its clinical evaluation.
INTRODUCTION
Triple negative breast cancers (TNBCs) 
comprise 15% of all breast tumors, and are defined at 
immunohistochemical level as tumors lacking detectable 
expression of hormone receptors, and no HER2 gene 
amplification [1-3]. Treatment of TNBC is based on 
chemotherapy, effective in these tumors because of their 
rapid proliferation rates and frequent derangements in 
DNA repair mechanisms [4]. Unfortunately, relapses are 
frequent, and resistance to the chemotherapeutic agents is 
often encountered in the metastatic setting [4-6]. These 
facts, together with the relatively poor knowledge of 
the driver molecular alterations present in TNBC have 
stimulated research to identify aberrant signaling networks 
that may be pharmacologically attacked [4]. 
A recent RNAi screen in search for agents 
that enhance paclitaxel activity in TNBC identified 
mithramycin as an agent able to sensitize TNBC cells to 
the antitumoral effect of taxanes [7]. Mithramycin is a 
reversible DNA binding antitumoral antibiotic approved 
since 1970 by the FDA, although severe side effects 
have limited its use in the clinic. Recently, promising 
in vitro and in vivo activity linked to specific modes 
of action [8, 9] have triggered its clinical evaluation in 
Ewing sarcoma, lung, esophagus and other thoracic 
malignancies [10]. The mode of action of mithramycin 
and several of its analogs involves a non-covalent 
interaction with GC-rich DNA regions located at the 
minor groove of DNA [11-13]. Several studies have 
pointed out that the basis for the antitumor properties 
of mithramycin and other analogs tested to date is the 
inhibition of replication and transcription processes 
during macromolecular biosynthesis by interacting with 
GC-rich nucleotide sequences, especially the site of union 
of Sp1 transcription factor [14-17]. As a consequence, 
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proteins whose expression is affected by this drug 
include various protooncogenes, proteins involved in 
angiogenesis or antiapoptotic processes, p53-mediated 
transcriptional responses, as well as multidrug resistant 
gene 1 (MDR-1) [18]. All these facts have fostered interest 
in the development of mithramycin analogs (mithralogs) 
with improved properties, focusing on those with lower 
toxicity, thus having better clinical chances than the 
wild type natural product [19]. Demycarosyl-3D-β-D-
digitoxosyl-mithramycin SK (EC-8042) is a mithramycin 
analog generated by combinatorial biosynthesis currently 
under development as antitumor agent. EC-8042 is a 
lead molecule in the quest for mithralogs with improved 
therapeutic window, since it is 10 times less toxic than 
mithramycin in vivo, while it is active both in vitro and 
in cancer xenograft models [20]. Moreover, recent gene 
expression array data have confirmed not only the role of 
Sp1 inhibition in the mechanism of action of EC-8042, 
but also other signaling networks relevant in cancer [21].
These precedents led us to explore the potential 
antitumoral action of EC-8042 against TNBC. Here we 
show that EC-8042 is active against a panel of TNBC 
cell lines and exerts antitumoral properties in TNBC cells 
xenografted in mice. Moreover, the drug augmented the 
action of compounds used clinically in the treatment of 
TNBC. Studies on the mechanism of action demonstrated 
that the drug exerted its action by a complex mechanism 
that involved cell cycle and proapoptotic effects. Together, 
the data suggest that EC-8042 could be considered for 
further development with the aim of being incorporated 
to the armamentarium used in the therapy of the disease.
RESULTS
Effect of EC-8042 on TNBC cell lines
The structure of demycarosyl-3D-β-D-digitoxosyl-
mithramycin SK (EC-8042) is shown in Figure 1A. To 
analyze the potential antineoplastic effect of the drug 
on TNBC, we evaluated its action on a panel of eight 
representative TNBC cell lines using MTT metabolization 
as readout of the effect of the drug on cell number. In 
addition, we also explored the action of EC-8042 on six 
additional breast cancer cell lines which belong to other 
subtypes of breast cancer (two hormone receptor positive, 
and four HER2+). Cells were plated and treated for 48 
(Figure S1) or 72 hours (Figure 1B) with different doses 
of EC-8042. Treatment with EC-8042 decreased MTT 
metabolization of all the cell lines studied in a dose-
dependent manner. At 72 hours of treatment, the drug 
IC
50
 values for all the TNBC cell lines were below 100 
nM (Figure 1C), indicating that EC-8042 was a potent 
inhibitor of the MTT metabolization in these cells. The 
IC
50
 values observed for EC-8042 were in general higher 
in non-TNBC breast cancer cell lines than in the case 
of the TNBC cell lines, indicating that EC-8042 could 
be better suited to be used in TNBC than in other breast 
cancer subtypes.
EC-8042 provokes cell cycle arrest in G2
The decrease in MTT metabolization caused by EC-
8042 could be caused by reduction in cell proliferation, 
increased cell death or a combination of both. To further 
analyze the antiproliferative mechanism of action of 
EC-8042 DNA stainings of MDA-MB231, HS578T and 
HBL100 cells were performed. Addition of EC-8042 to 
these cells increased the magnitude of the peak of the 
histogram corresponding to cells in the G2 or M phases 
(Figure 2A and 2B). A concomitant decrease of cells in 
the peak corresponding to the G1 phase was observed. 
In HBL100 cells, treatment with the drug also caused an 
increase in cells accumulating in G2/M at 100 nM. At 500 
nM, the drug provoked accumulation of cells in the subG1 
region of the histogram, suggestive of induction of cell 
death. This subG1 accumulation of cells treated at 500 
nM of the compound was also observed in MDA-MB231, 
although to a much lesser extent. 
The biochemical effects of EC-8042 on cell cycle 
regulatory proteins were evaluated in continuously 
growing cultures of MDA-MB231 and HBL100 cells. 
Western blotting analyses showed that treatment with 
EC-8042 caused a substantial decrease in the phosphatase 
cdc25C, together with an increase in Cyclin D3, Cyclin 
E, Cyclin A, Cyclin B, CDK2, and the phosphorylation 
of CDK1 at tyrosine 15. In MDA-MB231 cells the drug 
also increased the levels of p27 and Wee1 (Figure 2C). 
The above results confirmed that EC-8042 had an effect on 
proteins involved in the control of cell cycle progression. 
To more accurately define the cell cycle effects of 
EC-8042 we performed cell synchronization experiments, 
followed by release of the cells in the absence or presence 
of EC-8042, and analyses of the cell cycle profiles as well 
as markers of cell cycle progression at different times 
after release. In MDA-MB231 cells, double thymidine 
treatment caused accumulation of cells in G1 (Figure 
3A). At three and six hours after release the cells moved 
through S phase either in the absence or presence of 
EC-8042. At twelve hours after release, while most of 
the control cells have progressed through mitosis and 
accumulated at G1, cells chased in the presence of EC-
8042 accumulated in the G2/M phase of the cell cycle. 
Biochemical analyses of Cyclins D1-D3 involved in G1 
S cell cycle progression indicated that EC-8042 did 
not substantially decrease their levels for up to 12 hours 
(Figure 3B). At 24 hours of treatment, a decrease in Cyclin 
D1 was observed in cells treated with EC-8042. 
Sequential activation of CDK2 by Cyclin A and 
then CDK1 by Cyclins A and B are required to maintain 
Rb hyperphosphorylated to ensure cell cycle progression. 
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Then, when cells enter mitosis, the amounts of both 
cyclins rapidly decrease [22]. Treatment with EC-8042 
slightly delayed phosphorylation of Rb (Figure 3B). 
In control cells, levels of Cyclin A and Cyclin B rose, 
reaching a peak at 6 hours after release from the G1 
blockade. At 12 hours after chase, the amounts of Cyclin 
A and B decreased with respect to the levels present in 
cells at 6 hours. In EC-8042-treated cells the levels of both 
cyclins progressively increased and remained elevated for 
up to 24 hours of treatment (Figure 3B). 
Dephosphorylation of CDK1 at Y15, required for 
entry in mitosis, is controlled by the balance between the 
activity of the Wee1 kinase and the Cdc25c phosphatase. 
In control cells, pCDK1-Y15 levels decreased at 12 hours. 
In contrast, in cells treated with EC-8042 the levels of 
pCDK1-Y15 were sustained along the duration of the 
experiment (Figure 3B). Analyses of the phosphorylation 
of histone H3, which is used as a marker of cells in 
mitosis, indicated that cells treated with EC-8042 did not 
efficiently progressed into mitosis. Similar results were 
observed in HBL100 cells (Figure 3C and 3D). 
With the purpose of evaluating whether a 
relationship existed among the levels of the proteins 
analyzed above and involved in the regulation of G2M 
transition and the sensitivity of the TNBC cell lines 
to EC-8042, the total amount of those proteins was 
measured and plotted against IC
50
 values (Figure S2). 
However, no correlation was found among the levels of 
Wee1, pCDK1-Y15 and IC
50
 values for EC-8042. While 
statistically significant correlation failed to be observed 
in the case of SP1 and Cdc25c, a trend towards resistance 
to the action of EC-8042 was found in cells expressing 
higher levels of these proteins. On the other side, higher 
levels of Cdc25a appeared to facilitate the action of the 
drug. 
EC-8042 induces cell death
The increase in cells in the subG1 phase of the cell 
cycle, especially in HBL100 cells treated with EC-8042 
suggested that the drug stimulated cell death. As shown 
Figure 1: Action of EC-8042 in breast cancer cell lines. A. Structure of EC-8042. B. Dose-response analyses of the effect of EC-
8042 on the different breast cancer cell lines. Cells were treated with EC-8042 for 72 hours at the indicated doses. The data are plotted as the 
percentage of MTT metabolization with respect to control, vehicle-treated cells. Results are shown as the mean ± SD of quadruplicates of an 
experiment repeated three times. C. IC
50
 values obtained in the different breast cancer cell lines after 72 hours of incubation with EC-8042. 
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in Figure 4A, treatment with 500 nM of EC-8042 for 48 
hours augmented Annexin V staining of HBL100 cells, 
and also increased Annexin V staining of MDA-MB231 
cells, although to a much lesser extent (Figure 4A and 
4B). Treatment with 500 nM EC-8042 resulted in loss of 
mitochondrial membrane potential in both HBL100 and 
MDA-MB231 cells (Figure 4C), although the effect was 
substantially higher in the HBL100 cells, in line with the 
increased apoptotic effect of EC-8042 on such cell line. 
Members of the BCL2 family of proteins are known to 
participate in the regulation of MOMP. We observed that 
MCL1 and BCLX levels were down regulated in both cell 
lines after treatment with EC-8042 for 48 hours (Figure 
4D). We evaluated whether treatment with the drug 
caused an increase in caspase activity. Treatment with 
EC-8042 provoked an increase in caspase 3 and caspase 8 
activities (Figure 4E). The drug also provoked a decrease 
in the caspase inhibitor XIAP. Moreover, an increase in 
PARP cleavage, indicative of activation of caspases, 
was observed in both MDA-MB231 and HBL100 cells 
(Figure 4D). To evaluate to which extent caspases were 
responsible of the cell death induced by EC-8042 cells 
were incubated with the pancaspase inhibitor Z-VAD-
FMK before treatment with EC-8042. Addition of the 
caspase inhibitor did not inhibit EC-8042-induced cell 
death (Figure 4F) indicating that the effect of EC-8042 
mainly occurred through caspase-independent processes. 
In vivo antitumoral effect of EC-8042
The potential in vivo antitumoral effect of EC-8042 
was next investigated. Mice injected with MDA-MB231 
cells in the caudal mammary fat pad developed tumors 
within two weeks from the date of injection. Once tumors 
established and reached a mean volume of 100 mm3, mice 
were randomized to receive vehicle or EC-8042 (12 mg/
kg), intravenously every four days. Pharmacokinetic 
measurements of EC-8042 concentration in the tumors 
at 6 hours after the last treatment indicated that the drug 
Figure 2: Effect of EC-8042 on the cell cycle. A. Propidium iodide stainings of MDA-MB231, HBL100, and HS578T cells treated 
for 48 hours with 100 or 500 nM of EC-8042. B. Quantitative analyses of the action of EC-8042 on the distribution of the different cell 
cycle phases in the TNBC cell lines indicated. Cells were treated with the indicated concentrations of EC-8042 for 48 hours. C. Biochemical 
analyses of proteins involved in cell cycle progression. Cells were treated for 24 hours with the indicated concentrations of EC-8042, and 
lysates prepared. Analyses of the amounts of the different proteins studied were performed by Western blotting. GAPDH was used as a 
loading control.
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Figure 3: Effect of EC-8042 causes arrest of cells in the G2 cell cycle phase. A. Propidium iodide stainings of MDA-MB231 
cells synchronized in G1 by a double thymidine block, followed by release in the absence (Control) or presence of EC-8042 (500 nM). 
Chase times are shown at the left. B. Analyses of the levels of proteins involved in cell cycle progression at different chase times. Cells 
were synchronized in G1 by a double thymidine block, followed by release in the absence (Control) or presence of EC-8042 (500 nM). 
Western blotting was used to study the amounts of the different proteins analzyed. GAPDH was used as a loading control. C. Propidium 
iodide stainings of HBL100 cells synchronized in G1 by a double thymidine block, followed by release in the absence or presence of EC-
8042 (500 nM). D. Analyses of the levels of pHistone-H3 and GAPDH in HBL100 cells released in the absence or presence of EC-8042.
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Figure 4: Effect of EC-8042 on apoptotic cell death. A. Double Annexin V-propidium iodide stainings of MDA-MB231 and 
HBL100 cells treated for 48 hours with 100 or 500 nM EC-8042. B. Quantitative analyses of live/dead cells in cultures of MDA-MB231 
and HBL100 cells treated for 48 hours with 100 or 500 nM EC-8042. C. Analyses of mitochondrial membrane potential in cells treated for 
48 hours with the indicated concentrations of EC-8042. D. Effect of EC-8042 on the levels of several apoptosis-related proteins. MDA-
MB231 and HBL100 cells were treated for 48 hours with 100 or 500 nM EC-8042, and protein levels analyzed by Western blotting. E. 
Analyses of caspase 3 and caspase 8 activities in MDA-MB231 and HBL100 cells were treated for 48 hours with 100 or 500 nM EC-8042. 
Data are presented as mean ± SD of duplicates, and plotted as the fluorescence values obtained. F. Effect of Z-VAD-FMK on the viability 
of cells treated with EC-8042. Cells were preincubated with 10 μM of Z-VAD-FMK for 30 minutes prior to addition of 500 nM EC-8042. 
Incubations were extended for 48 hours, after which Annexin V-Propidium iodide double stainings were performed. 
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accumulated at doses higher that those deemed active 
in vitro (3.8 μg/g and 2.2 μg/g in two tumors from two 
different mice). Treatment with the drug exerted an 
inhibitory effect on tumor growth (Figure 5A). Body 
weight showed a slight decrease initially in animals treated 
with EC-8042, which recovered later (Figure S3). 
The definition of the molecular consequences 
of the treatment of EC-8042 on cell cycle regulators 
reported above guided in performing a pharmacodynamic 
assessment of the action of the drug in vivo. Tumors from 
control or EC-8042-treated mice removed 6h after the last 
treatment showed that tumoral samples from mice treated 
with the drug had increased levels of Wee1, pCDK1-Y15, 
p27, Cyclin A and Cyclin B (Figure 5B).
EC-8042 synergizes with standard of care drugs 
in vitro and in vivo
Antineoplastic treatments are often based on 
combinations of agents. To explore whether EC-8042 
potentiated the action of drugs used in the therapy of 
TNBC, drug combination experiments were performed, 
and the results analyzed by the Chou and Talalay 
algorithm [23] which is used to determine whether a 
drug combination is synergistic, additive or antagonistic 
or has no effect. Synergy was observed with docetaxel 
and gemcitabine (Figure 6A and 6B), while the action of 
vinorelbine (Figure S4) or carboplatin were not clearly 
augmented by EC-8042. We also tested the possibility that 
EC-8042 favored the action of other drugs which may be 
useful in TNBC such as the PI3K/mTOR inhibitor BEZ235 
or the tyrosine kinase inhibitor dasatinib. These studies, 
however, failed to indicate a synergistic antitumoral 
effect of the combination of EC-8042 with any of them 
(Figure S5). In vivo evaluation of the effect of EC-8042 
in combination with docetaxel or carboplatin was also 
performed. As shown in Figure 6C, the combination of 
EC-8042 with docetaxel had a stronger antitumoral effect 
than the individual treatments, despite the lack of schedule 
optimization of the drug combination. In contrast, and in 
agreement with the in vitro data, no potentiation of the 
effect of carboplatin by EC-8042 was observed (Figure 
S6A). Body weights of animals treated with these drugs or 
their combination were not substantially modified by the 
treatments (Figure S6B).
DISCUSSION
In this paper, we report the antitumoral action of 
the mithramycin analog EC-8042 in triple negative breast 
cancer. The rationale behind our study is double. On one 
hand is the recent identification that mithramycin shows 
an antitumoral action on TNBC cells [7]. On the other, 
the fact that mithramycin has a narrow therapeutic index 
moved us to test a mithralog selected by its lower toxicity 
and potentially higher therapeutic window [20].
EC-8042 exerted an antitumoral action both in vitro 
and in vivo. In vitro studies carried out in eight TNBC 
cell lines showed that the drug provoked a decrease in 
MTT metabolization values in a dose and time-dependent 
fashion. In vivo, the drug also caused a decrease in the 
Figure 5: Antitumorigenic effect of EC-8042 in vivo. A. MDA-MB231 cells were implanted in the mammary glands of female 
mice, and allowed to grow until tumors reached 100 mm3. Mice were randomized to receive vehicle (control) or 12 mg/Kg EC-8042 every 
4 days. Data are plotted as mean tumor volumes ± SD of eight mice/group. B. Analysis of Cyclin A, Cyclin B, Wee1, pCDK1-Y15, CDK2, 
p27 and GAPDH in lysates from tumors obtained from control or EC-8042-treated mice 6 hours after the last treatment. The numbers refer 
to the animal from which the analyzed tumor was dissected.
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growth of tumors developed from TNBC cells implanted 
in the mammary tissue of mice. Moreover, EC-8042 also 
favored the efficacy of taxanes in vitro and in vivo, and 
gemcitabine in vitro, two drugs currently used in the 
TNBC clinic. The effects in mice were observed without 
any significant effect of the drug on the weight of the 
mice, suggesting that the drug was well tolerated. 
The mechanism of the antitumoral effect of EC-
8042 was analyzed using flow cytometry as well as 
biochemical techniques. Treatment with the drug induced 
accumulation of cells with a diploid amount of DNA, 
indicating a blockade in G2 or M. Cell synchronization 
experiments using a double thymidine block, following 
by chasing of the cells in the absence or presence of 
the drug indicated that EC-8042 inhibited entry of cells 
in the M phase. Moreover, these experiments showed 
that cells treated with the drug evidenced a biochemical 
pattern compatible with G2 arrest. In fact, the drug caused 
accumulation of pCDK1-Y15. Phosphorylation of CDK1 
at that residue inhibits its activity, therefore preventing 
cells from entering mitosis [24]. Such phosphorylation is 
controlled by the balance between the kinase Wee1 and 
the phosphatase Cdc25c [25]. Importantly, treatment with 
the drug strongly decreased the amount of Cdc25c, which 
is required for the dephosphorylation of pCDK1-Y15. The 
levels of Cdc25c are regulated by various transcription 
factors, including Sp1 [26], the putative cellular target of 
mithramycin and analogs [27]. In addition to strong down 
regulation of the levels of Cdc25c, the drug provoked 
accumulation of Wee1 which altogether could inactivate 
CDK1. These in vitro findings were coincident with the 
accumulation of Wee1 and pCDK1-Y15 in tumoral samples 
from mice xenografted with MDA-MB231 cells and 
treated with EC-8042. 
In addition the effects of EC-8042 on the cell 
cycle, the drug also caused apoptosis, as indicated by 
accumulation of cells in the subG1 region of the histogram 
obtained by PI staining. However, the degree of apoptosis 
induced by the drug varied among different cell lines. 
In HBL100 cells, 500 nM of EC-8042 caused a strong 
induction of cell death, while in MDA-MB231 cells the 
effect was much lower. Evaluation of the mechanisms 
responsible for the cell death induced by the drug 
suggested that mitochondria could be involved in such 
process, as loss in MOMP was detected in both cell lines 
treated with the drug. Such loss in MOMP proportionally 
correlated with the degree of cell death induced by the 
drug. Interestingly, and even though clear differences were 
observed in MOMP loss in MDA-MB231 and HBL100 
cells treated with 500 nM of EC-8042, biochemical 
analyses of caspase 3 and caspase 8 activation offered 
quantitatively similar results. Moreover, cleavage of PARP 
Figure 6: Synergy of EC-8042 with standard of care drugs. HBL100 A. or MDA-MB231 B. cells were treated for 48 hours with a 
fixed ratio model of combinations of EC-8042, gemcitabine, or docetaxel. MTT metabolization analyses were performed and data analyzed 
using the Chou-Talalay algorithm. The results shown in the figure correspond to only a single dose combination example in which synergy 
was observed as indicated by CI values below 1. C. Analyses of the in vivo effect of drug combinations of tumor growth in nude mice 
implanted with MDA-MB231 cells. Tumors were allowed to grow to 100 mm3, and then mice were randomized to receive vehicle (control) 
or the indicated doses of the drugs. Data are plotted as mean tumor volumes ± SD of eight mice/group.
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which is often used as readout of caspase 3 activity was 
induced by the drug in both cell lines. These data indicated 
that activation of caspase cascades were analogous in both 
cell lines and the differences in cell death induction by 
EC-8042 in the two cell lines could not be explained by 
the mere activation of caspases. In support of the latter 
were the experiments carried out using the pancaspase 
inhibitor Z-VAD-FMK. This compound only marginally 
inhibited cell death induced by EC-8042 in both cell lines, 
suggesting that large part of the proapoptotic action of the 
drug was due to activation of caspase-independent routes.
The biochemical characterization of the effects 
of EC-8042 on TNBC cells led to the identification of 
proteins whose levels could be used to define sensitivity/
resistance to the action of the drug. Analyses of several 
proteins involved in G2M cell cycle progression and of 
SP1 indicated a certain degree of correlation among some 
of them and drug sensitivity. In fact, increased levels 
of Cdc25c and Sp1 appeared to confer resistance to the 
antitumoral action of EC-8042. It will be interesting to 
confirm such idea using genetic approaches to augment or 
decrease the levels of these proteins in TNBC cell models.
In summary, we show that the novel mithralog EC-
8042 exerts antitumoral activity in TNBC. Moreover, EC-
8042 behaved safely in mice, and augmented the action 
of some of the drugs commonly used in the therapy of 
TNBC. These biological properties of EC-8042 make this 
drug a worthy candidate for future development in the 
TNBC clinic.
MATERIALS AND METHODS
Reagents and antibodies
Cell culture media, fetal bovine serum (FBS) 
and tetramethylrhodamine ethyl ester (TMRE) were 
purchased from Invitrogen (Gaithersburg, MD). 
Propidium iodide (PI) and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) were from 
Sigma Chemical (St Louis, MO,USA). Annexin V-FITC, 
Matrigel, Z-VAD-FMK, AC-IETD-AF and AC-DEVD-
AFC were purchased from BD Biosciences (San Jose, 
CA). EC-8042 was provided by EntreChem SL (Oviedo, 
Spain) and obtained according to the procedure described 
before [20]. Carboplatin was from Pfizer (Madrid, Spain). 
Docetaxel was from Hospira UK Ltd (Warwickshire, 
United Kingdom). Vinorelbine was from Pierre Fabre 
(Barcelona, Spain). Gemcitabine was from Lilly (Madrid, 
Spain). BEZ235 and dasatinib were from LC Laboratories 
(Woburn, MA,USA). Other generic chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO, USA), 
Roche Biochemicals, or Merck (Darmstadt, Germany). 
The anti-GAPDH, anti-cyclin E, anti-Wee1, anti-cyclin 
B, anti-CDK2, anti-CDK4, anti-p21, anti-MCL1, anti-
BCL2, anti-Bax and anti-PARP antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
The anti-pCDK1 (Y15), anti-pH3, anti-p27, anti-Cdc25C, 
anti-Cdc25A, anti-SP1, anti-pRbS807/811, anti-pRbS780, 
anti-pRpb1, anti-Bid and anti-γH2Ax antibodies were 
from Cell Signalling Technologies (Beverly, MA, USA). 
The anti-cyclin A, anti-cyclin D1, anti-cyclin D3, anti-
BUBR1, anti-BCLX, anti-APAF1, anti-XIAP and Anti-
IAP1 antibodies were purchased from BD Biosciences 
(San Jose, CA, USA). The rabbit polyclonal anti-calnexin 
antibody was from Stressgen Biotechnologies Corporation 
(British Columbia, Canada). The anti-Bim and anti-Bak 
antibodies were from Calbiochem (La Jolla, CA, USA). 
Horseradish peroxidase conjugates of anti-rabbit and 
anti-mouse immunoglobulin G (IgG) were from Bio-Rad 
Laboratories (Hercules, CA, USA). 
Cell culture
All cell lines were cultured at 37°C in a humidified 
atmosphere in the presence of 5% CO2-95% air. Cells 
were grown in DMEM or in RPMI medium containing 
high glucose concentration (4,500 mg/liter) and antibiotics 
(penicillin at 100 mU/ml, streptomycin at 100 μg/ml) and 
supplemented with 10% FBS. Cell lines were provided by 
Drs. J. Losada and A. Balmain, (originally from Dr. J. W. 
Gray´s Laboratory who in turn obtained them from the 
ATCC or from collections development in the laboratories 
of Drs. S. Ethier and A. Gazdar, to avoid errors occurring 
when obtained through “second-hand” sources) [28]. Cell 
identities were verified by STR analyses.
Western blotting
MDA-MB231 and HBL100 cells were grown in 
DMEM with 10% of FBS and at 80% confluence were 
treated with EC-8042 for the times indicated. Cells were 
washed with phosphate-buffered saline (PBS) (NaCl, 137 
mM; KCl, 2.7 mM; Na2HPO4, 8 mM; KH2PO4, 1.5 mM) 
and lysed in ice-cold lysis buffer (20 mM Tris-HCl, pH 
7.0; NaCl, 140 mM; EDTA, 50 mM; 10% glycerol; 1% 
Nonidet P-40; 1 μM pepstatin; 1 μg/mL aprotinin; 1 μg/
mL leupeptin; 1 mM phenylmethyl sulfonyl fluoride; 1 
mM sodium orthovanadate). Lysates were centrifuged at 
10,000 xg at 4ºC for 10 minutes, and supernatants were 
transferred to new tubes. Samples were then boiled in 
electrophoresis sample buffer and run on SDS-PAGE gels 
at varying acrylamide concentrations, depending on the 
molecular weight of the proteins to be analyzed. After 
electrophoresis, the proteins in the gel were transferred to 
polyvinylidene difluoride membranes (PVDF) (Millipore 
Corporation, Bedford, MA, USA). Membranes were 
blocked in Tris-buffered saline with Tween (TBST) 
(100 mM Tris, pH 7.5; 150 mM NaCl; 0.05% Tween 20) 
containing 1% of bovine serum albumin (BSA) or 5% 
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skimmed milk for 1-3 hours and then incubated with the 
corresponding antibody for 2-16 hours. After washing 
three times with TBST during 10 minutes, membranes 
were incubated with HRP-conjugated anti-mouse or anti-
rabbit secondary antibodies for 30 minutes. After the 
secondary antibody, the membranes were washed three 
times with TBST and the bands were visualized by using 
enhanced chemiluminescence [29].
Cell proliferation, cell cycle and apoptosis assays
Cells were plated in 24-well plates at 10,000-
20,000 cells/well and cultured overnight in DMEM or 
RPMI + 10% FBS. The next day medium was replaced 
with DMEM or RPMI containing different concentrations 
of EC-8042. Cell proliferation was analyzed 48 and 72 
hours later by an MTT-based assay as described [30]. 
Unless otherwise indicated, the results are presented as 
the mean ± standard deviation (SD) of quadruplicates of a 
representative experiment that was repeated at least three 
times. 
To determine whether the combinations of EC-
8042 with BEZ235, dasatinib, carboplatin, docetaxel, 
vinorelbine, or gemcitabine were synergistic, additive, or 
antagonistic we used the CalcuSyn v2.0 software program 
(Biosoft, Ferguson, MO) as described [31]. Results are 
plotted as the mean ±SD values of quadruplicates from 
two experiments. 
For the analysis of the cell cycle profiles, cells were 
treated with EC-8042 during 48 hours and subsequently 
collected by pooling together the nonattached and 
attached cells. After washing with PBS, cells were fixed 
and permeabilized by ice-cold 70% ethanol overnight. 
Cells were centrifuged, resuspended in 500 µL of PBS 
containing 250 µg DNase-free RNAase A (Sigma-Aldrich) 
and incubated at room temperature for 2 hours. Then, 2.5 
µg of propidium iodide (PI; Sigma-Aldrich) were added. 
DNA content and cell cycle analyses were performed 
using a BD Accuri C6 flow cytometer and the C6 software 
(BD Biosciences).
To analyze the effect of EC-8042 on the different 
phases of cell cycle, cells were synchronized in G1/S. To 
enrich cells in G1/S, cells were treated with thymidine (2 
mM during 14 hours) as described [32]. Then the cells 
were treated with EC-8042 at different times and DNA 
content and cell cycle analyses were performed using a 
FACScalibur flow cytometer and the CellQuest software 
(BD Biosciences). 
For apoptotic analyses, MDA-MB231 and 
HBL100 cells were treated with EC-8042 for 48 hours 
and subsequently collected by pooling together the 
nonattached and attached cells. Then, cells were washed 
with PBS and resuspended in 100 µL of binding buffer 
(10 mM HEPES/NaOH, pH 7.4; 140 mM NaCl; 2.5 
mM CaCl2) containing 5 µL of Annexin V-fluorescein 
isothiocyanate (FITC; BD Biosciences) and 5 µL of 50 µg/
mL PI. Cells were incubated for 15-30 minutes in the dark. 
After adding another 400 µL of binding buffer, labeled 
cells were analyzed in a BD Accuri C6 flow cytometer. 
Analyses of mitochondrial membrane potential in MDA-
MB231 and HBL100 cells lines have been performed as 
described [33].
Caspase activity assay
MDA-MB231 and HBL100 cells were lysed in 
apoptosis lysis buffer (20 mM Tris, 140 mM NaCl, 10 mM 
EDTA, 10% glycerol, 1% NP40, pH 7.0) supplemented 
with protease inhibitors. Protein concentration was 
determined by de BCA assay (Pierce) and 50 μg of cell 
lysates were placed in 96-well plates in triplicate. The final 
volume of the lysates was taken to to 100 μl by 1x Caspase 
buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 0.1% CHAPS, 10% sucrose). One hundred μl of 2 
x caspase reaction buffer (50 mM HEPES pH 7.4, 300 mM 
NaCl, 2 mM EDTA, 0.2% CHAPS, 20% sucrose, 20 mM 
DTT and 10 μM fluorescently labelled caspase substrate 
Ac-IETD-AFC or Ac-DEVD-AFC) was added to each 
well containing cell lysates. The plate was shaken to mix 
the solution and incubated at 37ºC for 1 hour from light. 
Signals were measured at 400/505 nm in a fluorescent 
reader (BioTek).
Xenograft studies
Mice were manipulated at the animal facility of 
the Centro de Investigación del Cáncer of Salamanca 
following legal guidelines. Female BALB/c nu/nu 
mice (7 weeks old) were obtained from Charles River 
Laboratories (Wilmington, MA, USA). A total of 5x106 
MDA-MB231 cells in 100 μl of DMEM and 100 μl of 
Matrigel (BD Biosciences) were injected subcutaneously 
into the right and left flank of each mouse. When tumours 
reached a mean volume of 100 mm3, animals (n = 32) 
were randomized into four groups (with equal average 
tumour volumes) (vehicle n = 8, EC-8042 n = 8, docetaxel 
n = 8, and EC-8042+docetaxel n = 8). Mice were treated 
every four days intravenously with 12 mg/kg of EC-8042, 
and weekly, intraperitoneally with docetaxel 15 mg/kg. 
Tumour diameters were serially measured by calliper 
twice per week and tumour volumes were calculated by 
the following formula: volume = width2 x length/2. Mice 
were sacrificed on day 41. For biochemical and drug 
accumulation analyses, tumor samples were obtained 
after sacrifice of the animals by CO2 inhalation, and 6 
hours after being treated with the different drugs, and 
immediately frozen in liquid nitrogen. The tumors were 
minced, washed with PBS, and homogenized (Dispomix, 
L&M Biotech, Holly Springs, NC, USA) in ice-cold lysis 
buffer (1.5 ml/ 100 mg tumour). This homogenate was 
centrifuged at 10,000 xg for 20 minutes at 4ºC, and the 
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supernatants were transferred to new tubes.
Statistical analyses
Comparisons of continuous variables between 
two groups for the mice tumor model experiments were 
performed using a two-sided Student’s t-test. At least two 
independent experiments were performed for the in vivo 
studies. Differences were considered to be statistically 
significant when P values were less than 0.05. Statistical 
data are presented as the mean ± SD. Data were analyzed 
by the statistical software SPSS 21.0 (SPSS Inc., Chicago, 
IL).
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